RECRUITING

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Talk to us

Conditions

Hidradenitis Suppurativa (HS)INCB054707povorcitinibHidradenitis SuppurativaHidradenitisHS

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.

Official Title

A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Quick Facts

Study Start:2025-02-28
Study Completion:2028-02-28
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06855498

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Ability to comprehend and willingness to sign a written ICF for the study.
  2. * Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment.
  3. * Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
  4. * Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
  5. * Willingness to avoid pregnancy or fathering children as defined in the protocol.
  6. * Willingness and ability to comply with the study Protocol and procedures.
  1. * Had been permanently discontinued from study treatment during the parent study.
  2. * Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study.
  3. * Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:
  4. * Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
  5. * Live, attenuated vaccine.
  6. * Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.
  7. * Women who are pregnant (or who are considering pregnancy) or breastfeeding.
  8. * Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class.
  9. * Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
  10. * Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

Contacts and Locations

Study Contact

Incyte Corporation Call Center (US)
CONTACT
1.855.463.3463
medinfo@incyte.com
Incyte Corporation Call Center (ex-US)
CONTACT
+800 00027423
eumedinfo@incyte.com

Principal Investigator

Incyte Medical Monitor
STUDY_DIRECTOR
Incyte Corporation

Study Locations (Sites)

Investigator Site US004
Phoenix, Arizona, 85006
United States
Investigator Site US047
Scottsdale, Arizona, 85255
United States
Investigator Site US045
Fort Smith, Arkansas, 72916
United States
Investigator Site US009
Rogers, Arkansas, 72758
United States
Investigator Site US020
Laguna Niguel, California, 92677
United States
Investigator Site US036
Los Angeles, California, 90033
United States
Investigator Site US037
Oakland, California, 94611
United States
Investigator Site US032
San Diego, California, 92103
United States
Investigator Site US002
Boca Raton, Florida, 33486
United States
Investigator Site US035
Brandon, Florida, 33511
United States
Investigator Site US017
Hialeah, Florida, 33012
United States
Investigator Site US019
Hollywood, Florida, 33021-6746
United States
Investigator Site US041
Maitland, Florida, 32751
United States
Investigator Site US044
Margate, Florida, 33063
United States
Investigator Site US015
Miami, Florida, 33136
United States
Investigator Site US023
Miami, Florida, 33161
United States
Investigator Site US005
Tampa, Florida, 33613
United States
Investigator Site US001
Tampa, Florida, 33615
United States
Investigator Site US051
Marietta, Georgia, 30060-1047
United States
Investigator Site US049
Skokie, Illinois, 60077
United States
Investigator Site US039
West Dundee, Illinois, 60118
United States
Investigator Site US008
Indianapolis, Indiana, 46250
United States
Investigator Site US056
Bowling Green, Kentucky, 42104
United States
Investigator Site US013
Louisville, Kentucky, 40241
United States
Investigator Site US012
Baton Rouge, Louisiana, 70809
United States
Investigator Site US006
Metairie, Louisiana, 70006
United States
Investigator Site US057
New Orleans, Louisiana, 70115
United States
Investigator Site US038
Baltimore, Maryland, 21287-0876
United States
Investigator Site US053
Marriottsville, Maryland, 21104
United States
Investigator Site US046
Boston, Massachusetts, 02115
United States
Investigator Site US030
Boston, Massachusetts, 02215
United States
Investigator Site US048
Needham, Massachusetts, 02492
United States
Investigator Site US026
Quincy, Massachusetts, 02169
United States
Investigator Site US014
Fort Gratiot, Michigan, 48059
United States
Investigator Site US042
Waterford, Michigan, 48328
United States
Investigator Site US011
Minneapolis, Minnesota, 55455
United States
Investigator Site US016
Saint Louis, Missouri, 63110
United States
Investigator Site US007
Portsmouth, New Hampshire, 03801
United States
Investigator Site US024
East Windsor, New Jersey, 08520
United States
Investigator Site US040
Kew Gardens, New York, 11415
United States
Investigator Site US034
New York, New York, 10028-3135
United States
Investigator Site US050
Rochester, New York, 14642
United States
Investigator Site US031
Chapel Hill, North Carolina, 27516
United States
Investigator Site US028
Bexley, Ohio, 43209
United States
Investigator Site US055
Boardman, Ohio, 44512
United States
Investigator Site US025
Cincinnati, Ohio, 45219
United States
Investigator Site US022
Cleveland, Ohio, 44106
United States
Investigator Site US033
Columbus, Ohio, 43230-5317
United States
Investigator Site US018
Portland, Oregon, 97201
United States
Investigator Site US043
Murfreesboro, Tennessee, 37130
United States
Investigator Site US052
Arlington, Texas, 76011
United States
Investigator Site US021
Bellaire, Texas, 77401
United States
Investigator Site US010
Dallas, Texas, 75230-6862
United States
Investigator Site US054
Pflugerville, Texas, 78660
United States
Investigator Site US027
Norfolk, Virginia, 23502
United States
Investigator Site US003
Spokane, Washington, 99202
United States

Collaborators and Investigators

Sponsor: Incyte Corporation

  • Incyte Medical Monitor, STUDY_DIRECTOR, Incyte Corporation

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-28
Study Completion Date2028-02-28

Study Record Updates

Study Start Date2025-02-28
Study Completion Date2028-02-28

Terms related to this study

Keywords Provided by Researchers

  • INCB054707
  • povorcitinib
  • Hidradenitis Suppurativa
  • Hidradenitis
  • HS

Additional Relevant MeSH Terms

  • Hidradenitis Suppurativa (HS)